key: cord-0286359-641iw25f
authors: Uckun, Fatih M.; Orhan, Cemal; Powell, Joy; Sahin, Emre; Ozercan, Ibrahim H.; Volk, Michael; Sahin, Kazim
title: Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix
date: 2021-01-04
journal: bioRxiv
DOI: 10.1101/2021.01.03.425139
sha: 686f4adc37b0ec3a6670b5b12360568dfde941b8
doc_id: 286359
cord_uid: 641iw25f

Here, we demonstrate that the two distinct formulations of our anti-sepsis drug candidate Rejuveinix (RJX) have a very favorable safety profile in Wistar Albino rats at dose levels comparable to the projected clinical dose levels. 14-day treatment with RJX-P or RJX-B similarly elevated the day 15 tissue levels of the antioxidant enzyme superoxide dismutase (SOD) as well as ascorbic acid in both the lungs and liver in a dose-dependent fashion. The activity of SOD and ascorbic acid levels were significantly higher in tissues of RJX-P or RJX-B treated rats than vehicle-treated control rats (p <0.0001). There was no statistically significant difference between tissues SOD activity or ascorbic acid levels of rats treated with RJX-P vs. rats treated with RJX-B (p >0.05). The observed elevations of the SOD and ascorbic acid levels were transient and were no longer detectable on day 28 following a 14-day recovery period. These results demonstrate that RJX-P and RJX-B are bioequivalent relative to their pharmacodynamic effects on tissue SOD and ascorbic acid levels.

Sepsis represents a strong inflammatory response to an infection with a potentially fatal outcome due to its complications, including acute respiratory distress syndrome (ARDS), septic Disposition:

The remaining dose formulations were discarded after completion of the dose administration. Table 5 compares the quantitative composition of RJX-P and RJX-B.

The toxicity of RJX-P and RJX-B formulations were examined at the Bingol University Experimental Animal Center in Bingol, Turkey with the approval of the Animal Care and Use Committee (IACUC) at the Bingol University (23092020-E-2310). 8-week old Wistar albino rats were used in this study. A total of 100, 20 rats per group were used. There were 2 cohorts. One cohort was treated for 14 days and sacrificed on day 15. The second cohort was treated for 14 days and sacrificed on day 28 following a 2 week recovery period. In each cohort, there were 5 treatment groups, including one control group and 4 RJX treatment groups. The collective group designation for cohort 1 + cohort 2 (N=100) was as follows: Rats in Cohort 1 (5 males and 5 females from each group listed above) were observed for clinical signs of toxicity daily, weighed biweekly, and sacrificed on day 15 or day 28 to determine the toxicity of RJX by examining their blood chemistry profiles, blood counts, and histopathological examinations of tissue specimens. Blood was collected after decapitation by cervical dislocation.

All laboratory analyses were performed at the Firat University (Elazig, Turkey). The blood chemistry profiles were examined using automated laboratory methods (Samsung Labgeo PT10,

were determined using an Exigo Hematology Analyzer (Sweden).

Blood samples were used for safety pharmacology and serum chemistry tests. Serum concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and total bilirubin, were assayed using an automated chemistry analyzer (Samsung LABGEO PT10, Samsung Electronics Co., Suwon, Korea). Safety pharmacology labs, tissue activity of superoxide dismutase (SOD), and tissue ascorbic acid levels were determined to examine the effects of RJX-P and RJX-B. The activities of superoxide dismutase (SOD) were determined by quantitative enzyme-linked immunosorbent assays (ELISA, Bio-Tek Elx800 Table 1 for details of target formulation content.

The purpose of the rat toxicity study is to compare the toxicity of two RJX formulations to rule out unexpected, unusual severe toxicities at the clinically applicable dose levels. The toxicity of RJX in rodents has been extensively studied. The no observed adverse effect level (NOAEL) was >5 mL/kg in both Sprague Dawley rats (when administered via intra-arterial route daily for 21 days) and Beagle dogs (when administered via intra-arterial route daily x 28 days). The HED of the >5 mL/kg NOAEL in rats is 0.8 mL/kg and the HED of the ≥ 5 mL/kg NOAEL in dogs is 2.7 mL/kg. The safety of RJX in human subjects was examined in a Phase 1 study in healthy human volunteers and the MTD was determined to be 0.5 mL/kg. In a clinical study in COVID-19 patients (RPI015), RJX is being used at a fixed dose level of 20 mL/dose/patient. This corresponds to an estimated average per kg dose level of 0.25 mL/kg to 0.33 mL/kg for an adult patient weighing 60-80 kg. The selected higher dose level in rats is 2.5 mL/kg, which corresponds to a human equivalent dose of 2.5 x 0.16 mL/kg = 0.4 mL/kg. The dose is selected as a dose level ~20% higher than the estimated average clinical dose.

The selected lower dose level in rats is 1.25 mL/kg, which corresponds to a human equivalent dose of 0.2 mL/kg. This dose was selected as a dose level ~20% lower than the estimated low dose level in the clinical study for an 80 kg adult patient. Both dose levels are substantially higher than the 0.07 mL/kg (i.e., 0.42 mL/kg of a 1:6 diluted solution) effective dose level at which RJX was shown to both prevent and reverse cytokine storm, acute lung injury, and multi-organ dysfunction in a model of LPS-galactosamine induced sepsis, septic shock, ARDS, and multiorgan failure [18-uckun Frontiers-2020]. The same dose levels were selected for the testing of RJX-B for comparison purposes. As the concentration of the active ingredients is lower in RJX-B, the safety profile of this new formulation was postulated to be similar or better than the safety profile of RJX-P.

Statistical analysis includes analysis of variance (ANOVA) and/or, nonparametric analysis of variance (Kruskal-Wallis) using the SPSS statistical program (IBM, SPPS Version 21 

Toxicity. RJX-P and RJX-B, when administered as daily intraperitoneal bolus injections for 14 consecutive days with or without a 14-day recovery time were not toxic to female or male Wistar Albino rats at 0.25 mL or 0.5 mL dose levels. None of the 40 rats treated with RJX-P or 40 rats treated with RJX-B showed any signs of morbidity. Groups of 20 rats were sacrificed on day 15 and day 28 (14 day recovery period group), respectively. The majority of the RJX-P or RJX-Btreated rats, gained weight during the 0-14 day, 14-28 day and, 0-28 day observation period. The average weight gain was 4.20 g (2.1%) for vehicle-treated control rats, and 4.59 g (2.3%) and 4.55 g (2.3%) for rats treated with the higher dose of RJX-P or RJX-B for a 0-28 day period ( Table 6 and Figure 1 ). As shown in Table 7 and Table 8 , the blood chemistry and hematology profiles of these rats did not suggest any system-specific toxicity. In particular, RJX-P or RJX-B-treated rats showed: (a) normal serum BUN and creatinine levels consistent with absence of renal toxicity; and (b) normal WBC, ANC, ALC, and RBC counts consistent with absence of hematologic toxicity.

Histopathological examination of multiple tissues from RJX-P or RJX-B -treated rats in the day 15 group (n = 20) ( Table 9 , Figures 2-6) or day 28 groups (n=10) (Table 10) did not reveal any toxic lesions.. Thus, RJX-P and RJX-B were not toxic to rats at dose levels up to 0.5 mL/kg.

Pharmacodynamics. 14-day treatment with RJX-P and RJX-B similarly elevated the Day 15 tissue activities of the antioxidant enzyme superoxide dismutase (SOD) as well as ascorbic acid levels in both the lungs and liver in a dose-dependent fashion (Table 11, Figure 7, Figure 8 ). The activity of SOD and ascorbic acid were significantly higher in tissues of RJX-P or RJX-B treated rats than vehicle-treated control rats (p<0.0001). There was no statistically significant difference between SOD activity or ascorbic acid tissue levels of rats treated with RJX-P vs. rats treated with RJX-B (p>0.05). The observed elevations of the SOD activity and ascorbic acid levels were transient and were no longer detectable on day 28 following a 14-day recovery period (Figure 9,   Figure 10 ). These results demonstrate that RJX-P and RJX-B are bioequivalent relative to their pharmacodynamic effects on tissue SOD activity and ascorbic acid levels.

Patients with high-risk COVID-19 are in urgent need of effective treatment strategies that can prevent the development of ARDS and multi-organ failure [1] [2] [3] [4] . Recently, we demonstrated that RJX prevents in a mouse model of sepsis the marked increase of each of proinflammatory cytokines like IL-6, TNF-α, and TGF-β in the serum as well as lungs and liver when treatments are initiated prophylactically prior to the injection of a fatal dose of LPS-GalN [3] . Notably, the activities of the antioxidant enzymes SOD, CAT, and GSH-Px were reduced after injection of LPS-GalN consistent with severe oxidative stress. RJX substantially improved the abnormally reduced activities of the antioxidant enzymes SOD, CAT, and GSH-Px, and levels of ascorbic acid. These results established RJX as a potent antioxidant with strong anti-inflammatory activity. The present study demonstrates that a 14-day treatment with RJX formulations increases tissue levels of ascorbic acid as well as SOD.

RJX-P and RJX-B were bioequivalent relative to their pharmacodynamic effects on tissue SOD activity and ascorbic acid levels. These results confirm 

R J X - P ( 0 . 5 m L ) R J X - P ( 0 . 2 5 m L ) R J X - B ( 0 . 5 m L ) R J X - B ( 0 . 2 5 m L ) C o n t r o l ( N S ) R J X - P ( 0 . 5 m L ) R J X - P ( 0 . 2 5 m L ) R J X - B ( 0 . 5 m L ) R J X - B ( 0 . 2 5 m L )

Clinical Impact Potential Of Rejuveinix (RJX) For Prevention Of Fatal Acute Respiratory Distress Syndrome (ARDS) And Multi-Organ Failure In Covid-19 Patients

Rationale For A Randomized, Placebo-Controlled, Phase 2 Study Of Rejuveinix (RJX) in COVID-19 Patients With Acute Lung Injury And Hypoxemic Respiratory Failure

Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi-Organ Failure

Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation